Puma Biotechnology, Inc.

Release Summary

Puma Biotechnology presented results from its Phase II SUMMIT trial of its lead drug candidate PB272 (neratinib) in HER2 mutant, HER2 non-amplified, metastatic cancer at the 2017 AACR Annual Meeting.

Puma Biotechnology, Inc.